These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35752350)

  • 1. Role of olmesartan in ameliorating diabetic nephropathy in rats by targeting the AGE/PKC, TLR4/P38-MAPK and SIRT-1 autophagic signaling pathways.
    Abo El-Nasr NME; Saleh DO; Hashad IM
    Eur J Pharmacol; 2022 Aug; 928():175117. PubMed ID: 35752350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways.
    Abo El-Nasr NME; Saleh DO; Mahmoud SS; Nofal SM; Abdelsalam RM; Safar MM; El-Abhar HS
    Eur J Pharmacol; 2020 May; 874():173010. PubMed ID: 32067934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of PKC/TLR-4/NF-kB signaling by sulbutiamine improves diabetic nephropathy in rats.
    Ghaiad HR; Ali SO; Al-Mokaddem AK; Abdelmonem M
    Chem Biol Interact; 2023 Aug; 381():110544. PubMed ID: 37224990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways.
    Li J; Bao L; Zha D; Zhang L; Gao P; Zhang J; Wu X
    Int Immunopharmacol; 2018 Feb; 55():9-19. PubMed ID: 29207360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.
    Lakshmanan AP; Thandavarayan RA; Watanabe K; Sari FR; Meilei H; Giridharan VV; Sukumaran V; Soetikno V; Arumugam S; Suzuki K; Kodama M
    Mol Cell Endocrinol; 2012 Jan; 348(1):104-11. PubMed ID: 21827824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells.
    Ahad A; Ahsan H; Mujeeb M; Siddiqui WA
    Chem Biol Interact; 2015 Oct; 240():292-303. PubMed ID: 26341651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crocin mediated amelioration of oxidative burden and inflammatory cascade suppresses diabetic nephropathy progression in diabetic rats.
    Abou-Hany HO; Atef H; Said E; Elkashef HA; Salem HA
    Chem Biol Interact; 2018 Mar; 284():90-100. PubMed ID: 29409856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.
    Malik S; Suchal K; Khan SI; Bhatia J; Kishore K; Dinda AK; Arya DS
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F414-F422. PubMed ID: 28566504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of Early Markers of Diabetic Nephropathy by Linagliptin in Fructose-Streptozotocin-Induced Type 2 Diabetic Rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Nephron; 2019; 141(4):273-286. PubMed ID: 30699409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
    Zhu Y; Li ZL; Ding A; Yang H; Zhu WP; Cui TX; Zhang HT; Zhang H
    Drug Des Devel Ther; 2019; 13():3657-3667. PubMed ID: 31695333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced beta 2 glycoprotein I improves diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway.
    Wang T; Chen SS; Chen R; Yu DM; Yu P
    Int J Clin Exp Pathol; 2015; 8(3):2321-33. PubMed ID: 26045739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
    Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nepeta angustifolia C. Y. Wu improves renal injury in HFD/STZ-induced diabetic nephropathy and inhibits oxidative stress-induced apoptosis of mesangial cells.
    Huang S; Tan M; Guo F; Dong L; Liu Z; Yuan R; Dongzhi Z; Lee DS; Wang Y; Li B
    J Ethnopharmacol; 2020 Jun; 255():112771. PubMed ID: 32201300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ameliorative effect of montelukast against STZ induced diabetic nephropathy: targeting HMGB1, TLR4, NF-κB, NLRP3 inflammasome, and autophagy pathways.
    Awad AM; Elshaer SL; Gangaraju R; Abdelaziz RR; Nader MA
    Inflammopharmacology; 2024 Feb; 32(1):495-508. PubMed ID: 37498374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fangchinoline Protects Against Renal Injury in Diabetic Nephropathy by Modulating the MAPK Signaling Pathway.
    Jiang Y; Liu J; Zhou Z; Liu K; Liu C
    Exp Clin Endocrinol Diabetes; 2020 Aug; 128(8):499-505. PubMed ID: 30049003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
    Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
    J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moringa oleifera impedes protein glycation and exerts reno-protective effects in streptozotocin-induced diabetic rats.
    Ahmad S; Pandey AR; Rai AK; Singh SP; Kumar P; Singh S; Gulzar F; Ahmad I; Sashidhara KV; Tamrakar AK
    J Ethnopharmacol; 2023 Apr; 305():116117. PubMed ID: 36584917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice.
    Song W; Wei L; Du Y; Wang Y; Jiang S
    Int Immunopharmacol; 2018 Oct; 63():227-238. PubMed ID: 30107367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
    Hofni A; El-Moselhy MA; Taye A; Khalifa MM
    Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.